Investors

About AVROBIO

AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose.

Stock Quote

Press Releases
June 27, 2018
AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors

Industry leader brings expertise in finance, M&A and operations as former CFO of gene therapy company, AveXis, Inc. CAMBRIDGE, Mass. , June 27, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc.  (NASDAQ:AVRO), a Phase 2 clinical stage gene therapy company focused on developing potentially curative

June 20, 2018
AVROBIO, Inc. Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass. , June 20, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose, today announced the pricing of its

Stock Chart

Copyright Nasdaq. Minimum 15 minutes delayed.

Events
More events are coming soon.